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risk for cardiovascular events. Adipose tissue plays a central role in the obe-
sity-related metabolic abnormalities and it’s known that Mineralocorticoid
Receptor (MR) activation affects adipocyte differentiation and function. In
particular, MR blockade has shown significant promise in limiting adipocyte
dysfunction and MetS in preclinical models. Moreover it has been shown that
adipose tissue secretome shows a paracrine effect on vascular system and car-
diac function. In our study we showed that MR expression is increased in vis-
ceral adipose tissue (VAT) in a preclinical mouse model of MetS and in obese
patients. Thus, we generated a double transgenic mouse model with a condi-
tional and inducible overespression of MR in adipose tissue, demonstrating
that, even in the absence of high fat diet HFD, increased expression of MR in
adipose tissue contributes to MetS development with multiple metabolic
abnormalities, including visceral obesity and body weight gain, glucose
intolerance and insulin resistance as well as dyslipidemia. Moreover we iden-
tified prostaglandin D2 synthase (PTGDS) as a novel MR target gene in adi-
pocytes and AT56, a specific inhibitor of PTGDS enzymatic activity, blunted
adipogenic aldosterone effects. Finally, translational studies showed that
expression of MR and PTGDS are strongly correlated in adipose tissues from
obese patients. In consideration of our results other analyses are necessary to
investigate the effect of the MR overexpressing model-specific adipokine pro-
file on cardiac function. Of particular interest will be the study of the cross-
talk between the epicardial adipose tissue (EAT) and the adjacent myocardium
by using supernatants obtained from MR overexpressing mice EAT incubation
to test the paracrine effect of adipokines on cardiac myocytes function.
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Background/Objectives: Lymphocytes play a critical role in visceral adi-
pose tissue inflammation. The CD28 costimulatory molecule is required for
lymphocyte activation and for the development of a functional regulatory T
cells (Treg) compartment; however its role during obesity is unknown.
Methods: During diet-induced obesity, we investigated the effects of
selective interference with CD28 signaling using knock-out mice (Cd28KO)
and a CTLA4-Ig fusion protein inhibiting CD28-B7 interactions.
Results: Cd28 deficiency decreased pathogenic T-cells and Treg content
within adipose tissue without changing macrophages number. Cd28KO epi-
didymal but not subcutaneous fat was characterized by enlarged adipocytes,
reduced levels of inflammatory cytokines and increased Glut4, adiponectin
and lipogenic enzymes mRNA levels. This was associated with reduced
inflammation, fat accumulation and enhanced glucose metabolism in liver.
Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injec-
tions reduced the number T-cells in epididymal adipose tissue but not inflam-
matory cytokines levels and failed to improve liver fat accumulation.
Conclusions: Deletion of CD28 creates a new pro/anti-inflammatory
balance in epididymal adipose tissue and liver and exerts a protective effect
against hepatic steatosis.
0321
Imidazoline-like drug improves insulin sensitivity through a direct sti-
mulation of adiponectin secretion in primary adipocytes
Maud Weiss, Florian Traversi, Pascal Bousquet, Hugues Greney, Nathalie
Niederhoffer
Labo de Neurobiologie et Pharmacologie Cardiovasculaire (EA 7296),
Strasbourg, France
Introduction: Altered adiponectin signaling has been proposed as a key
factor in the development of metabolic syndrome. We previously showed that
one imidazoline I1 receptor (I1R) ligand, LNP509, can improve insulin sensi-
tivity and glucose tolerance partly through increased adiponectin plasma level.
The objective of this study was to explore direct actions of I1R ligands on adi-
pocytes.
Methods: Experiments were carried out in primary adipocytes isolated
from the epididymal white adipose tissue of aged male Wistar rats. Expression
of I1R on adipocytes was verified with binding assays. I1R ligand effect was
evaluated by treating adipocytes with increasing concentrations of LNP509
±I1R antagonist efaroxan (10-4 M). To identify the intracellular signaling path-
ways involved in the action of LNPs, wortmannin (PI3K-inhibitor), IBMX
(phosphodiesterase blocker) and AS1842856 (FOXO1 inhibitor) were added
45 min prior LNP509 exposure. After 3h, adiponectin content was measured
in the culture medium by ELISA assay.
Results: Competition binding assays confirmed the expression of I1R in adipo-
cyte membrane. Treatment by LNP509 dose-dependently induced adiponectin
secretion: from 18±5 ng/ml at 10-9 M to 66±15 ng/ml at 10-4 M; p≤0.05 vs medium
alone (25 ng/ml). The adiponectin secretion induced by the highest LNP509
concentration was similar to the one elicited by 10 μM insulin (61 ng/ml); the
secretion was totally prevented by a pretreatment with efaroxan (10-4 M). The
LNP509-induced adipokine secretion was unchanged by wortmannin, but was
reduced after phosphodiesterase and FOXO1 blockade (–80% and –44% respec-
tively, compared to LNP509 alone).
Conclusion: LNP509, through I1R, promotes adiponectin secretion by
inhibiting cAMP and SIRT1/FOXO1 pathways. These effects could lead to
PPARγ  activation in order to promote adiponectin synthesis. Future studies
should confirm the proposed signaling pathways.
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